U.S. CDC Preferentially Recommends Influenza Vaccines for Seniors
New Jersey-based Seqirus announced yesterday that the U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) had included FLUAD® QUADRIVALENT as a preferentially recommended seasonal influenza vaccine for adults 65 years of age and older.
The preferential recommendation for FLUAD QUADRIVALENT for seniors is based on the clinical benefits compared to standard egg-based influenza vaccines, as demonstrated within the total body of evidence.
'Prior to this announcement, seasonal flu vaccine guidelines for individuals 65 and older had not been updated since 2010.'
"It is critical that we do everything we can to protect vulnerable populations like older adults against influenza," commented Gregg Sylvester, MD, Chief Health Officer, Seqirus, in a press release on June 22, 2022.
"Today's recommendation is evidence of the ACIP's commitment to providing clear, evidence-backed guidance to protect public health."
"We are proud to offer one of the enhanced flu vaccines that were preferentially recommended by the ACIP for adults 65 years and above in the USA."
FLUAD QUADRIVALENT is created explicitly for seniors using Seqirus' MF59® adjuvant, designed to help strengthen, broaden and lengthen the immune response to influenza vaccination.
Immunosenescence, the age-associated decline of the immune system, may result in a reduced immune response to antigens in the vaccine.
Since it takes about two weeks after vaccination for antibodies to develop in the body that helps protect against influenza virus infection, it is recommended that people get vaccinated before influenza begins spreading in their community.
The CDC recommends that people get vaccinated by the end of October each year.
FLUAD is proven to be safe and effective and has an extensive clinical legacy, with more than 225 million doses distributed and licensure in over 30 countries since 1997.
Note: According to the ACIP, if one preferentially recommended influenza vaccine is unavailable for adults 65 years and older, then any other age-appropriate influenza vaccine should be used. This information was manually curated for mobile readers.